# A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis

> **NCT05095246** · PHASE1 · WITHDRAWN · sponsor: **Krystal Biotech, Inc.**

## Conditions studied

- Cystic Fibrosis

## Interventions

- **BIOLOGICAL:** KB407 (Nebulization)

## Key facts

- **NCT ID:** NCT05095246
- **Lead sponsor:** Krystal Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-08
- **Primary completion:** 2024-07-01
- **Final completion:** 2024-10-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Pandemic, logistical, and recruitment challenges
- **Last updated:** 2023-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05095246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05095246, "A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05095246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*